

**Remarks**

Applicants request entry of the amendments. The amendments place the application in condition for allowance as suggested by the Examiner in the comments accompanying the Office communication.

Applicants have amended the specification at page 12 as suggested by the Examiner. One of skill in the art was familiar with the 72K protein of the E2A region of adenovirus as one of the proteins encoded by E2, and clearly the word "especially" in this paragraph identifies that other regions of E2 exist and can be selected for use in the cell lines of the invention.

Applicants have amended claims 36, 45, and 61 to recite particular gene or adenoviral regions as "the only adenoviral genes that have been rendered non-functional." These amendments address the Examiner's comments at pages 3-4 of the Office Action. Furthermore, claim 45 includes the Examiner's suggested language with respect to the optional E3 gene.

No new matter enters by these amendments.


All the objections and rejections were addressed in the Reply filed June 22, 2006.

Application No. 08/397,225  
Reply and Amendment dated November 20, 2006  
Reply to Office Communication of July 7, 2006

If there are any additional fees due with the filing of this document, including fees for the net addition of claims, applicants respectfully request that any and all fees be charged to Deposit Account No. 50-1129. If any extension of time request or any petition is required for the entry of this paper or any of the accompanying papers, applicants hereby petition or request the extension necessary. The undersigned authorizes any fee payment from Deposit Account No. 50-1129.

Respectfully submitted,  
**Wiley Rein & Fielding LLP**

Date: November 20, 2006

By:   
David J. Kulik  
Reg. No. 36,576  
Heather H. Ramirez  
Reg. No. 57,369

**WILEY REIN & FIELDING LLP**  
Attn: Patent Administration  
1776 K Street, N.W.  
Washington, D.C. 20006  
Telephone: 202.719.7000  
Facsimile: 202.719.7049

WRFMAIN 12569160.1